References
- Estes, C., et al. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md.), 67(1), 123–133. https://doi.org/10.1002/hep.29466
- Harrison, S. A., et al. (2021). Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. Journal of hepatology, 75(2), 284–291. https://doi.org/10.1016/j.jhep.2021.02.034
- Schaapman, J. J., Tushuizen, M. E., Coenraad, M. J., & Lamb, H. J. (2021). Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease. Journal of magnetic resonance imaging: JMRI, 53(6), 1623–1631. https://doi.org/10.1002/jmri.27292
- Wood, J. C., et al. (2005). MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood, 106(4), 1460–1465. https://doi.org/10.1182/blood-2004-10-3982
- Hoad, C. L., et al. (2015). A study of T₁ relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR in biomedicine, 28(6), 706–714. https://doi.org/10.1002/nbm.3299
- Banerjee, R., et al. (2014). Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. Journal of Hepatology, 60(1), 69-77. https://doi.org/10.1016/j.jhep.2013.09.002
- Pavlides, , et al. (2017). Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver International, 37(7), 1065-1073. https://doi.org/10.1111/liv.13284
- Harrison, S. A., et al. (2018). Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PloS one, 13(9), e0203054. https://doi.org/10.1371/journal.pone.0203054
- Bachtiar, V., et al. (2019). Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS One, 14(4), e0214921. https://doi.org/10.1371/journal.pone.0214921
- Pavlides, M., et al. (2016). Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. Journal of hepatology, 64(2), 308–315. https://doi.org/10.1016/j.jhep.2015.10.009
- Jayaswal, A., et al. (2020). Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. Liver International, 40(12), 3071-3082. https://doi.org/10.1111/liv.14625
- Imajo, K., et al. (2021). Quantitative multiparametric MRI can aid NASH diagnosis in a Japanese cohort. World Journal of Gastroenterology, 27(7), 609–623. https://doi.org/10.3748/wjg.v27.i7.609
- Andersson, A., et al. (2021). Clinical utility of MRI biomarkers for identifying NASH patients at high risk of progression: A multi-center pooled data and meta-analysis. Clinical Gastroenterology and Hepatology. Advance online publication. https://doi.org/10.1016/j.cgh.2021.09.041
- Dennis, A., et al. (2021). Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis. Frontiers in Endocrinology, 11, 575843. https://www.frontiersin.org/articles/10.3389/fendo.2020.575843
- Beyer, C., et al. (2021). Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. PloS one, 16(4), e0249491. https://doi.org/10.1371/journal.pone.0249491
- Harrison, S. A., et al. (2020). NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. Hepatology (Baltimore, Md.), 71(4), 1198–1212. https://doi.org/10.1002/hep.30590
- Harrison, S. A., et al. (2021). Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. The American journal of gastroenterology, 116(12), 2399–2409. https://doi.org/10.14309/ajg.0000000000001375